StoxOnyx Biotec Limited
NSE: ONYX · Unclassified
Ask the data
Instant answers about Onyx Biotec Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY25 | FY26 | |
|---|---|---|
| Revenue | 62.0 | 69.5 |
| EBITDA | 10.3 | 3.4 |
| Operating margin | 16.7% | 4.9% |
| Interest | 2.0 | 1.2 |
| Depreciation | 3.0 | 3.0 |
| Profit before tax | 6.5 | -0.4 |
| Tax | 1.5 | -0.2 |
| Net profit | 5.0 | -0.2 |
| EPS ₹ | 3.30 | -0.12 |
| Operating cash flow | 1.4 | -1.5 |
| Capex | 1.1 | 5.0 |
| Dividend paid | 0.0 | 0.0 |
| Total assets | 91.2 | 95.2 |
| Equity | 55.6 | 55.4 |
Half-yearly performance
last 4 half years · ₹ crore| H1 FY25 | H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|---|
| Revenue | 30.1 | 31.8 | 34.6 | 34.9 |
| Operating profit | 5.7 | 4.6 | 0.9 | 2.5 |
| Operating margin | 18.9% | 14.6% | 2.7% | 7.0% |
| Other income | 1.0 | 0.2 | 0.2 | 0.2 |
| Interest | 1.4 | 0.6 | 0.6 | 0.7 |
| Depreciation | 1.5 | 1.5 | 1.6 | 1.5 |
| Profit before tax | 3.8 | 2.7 | -0.9 | 0.5 |
| Tax | 0.8 | 0.7 | -0.0 | -0.2 |
| Net profit | 3.0 | 2.0 | -0.9 | 0.7 |
| EPS ₹ | 2.24 | 1.31 | -0.50 | 0.38 |
| Revenue YoY | — | — | 14.7% | 9.7% |
| Profit YoY | — | — | -130.1% | -65.0% |
Returns & margins
trailing-twelve-month, per half year| H2 FY25 | H1 FY26 | H2 FY26 | |
|---|---|---|---|
| ROE | 8.9% | 2.0% | -0.4% |
| ROCE | 12.4% | 4.1% | 1.1% |
| Net margin | 8.0% | 1.6% | -0.3% |
| EBITDA margin | 16.7% | 8.4% | 4.9% |
| Debt / equity | 0.22 | 0.29 | 0.27 |
| Interest coverage | 4.27 | 2.49 | 0.64 |
| Asset turnover | 0.68 | 0.72 | 0.73 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|
| Share capital | 13.3 | 18.1 | 18.1 | 18.1 |
| Other equity / reserves | 14.9 | 37.5 | 36.6 | 37.3 |
| Total equity | 28.3 | 55.6 | 54.7 | 55.4 |
| Borrowings | 30.2 | 12.5 | 15.7 | 15.2 |
| Current liabilities | 28.7 | 25.7 | 28.9 | 32.5 |
| Non-current liabilities | 20.8 | 9.9 | 8.5 | 7.2 |
| Total assets | 77.8 | 91.2 | 92.1 | 95.2 |
| Property, plant & equipment | 41.9 | 40.9 | 39.8 | 39.2 |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventories | 11.8 | 16.1 | 12.1 | 14.0 |
| Receivables | 18.2 | 20.2 | 26.8 | 27.5 |
| Cash & equivalents | 1.5 | 8.6 | 7.2 | 4.0 |
Cash flow
annual · ₹ crore · line = free cash flow| FY25 | FY26 | |
|---|---|---|
| Cash from operations | 1.4 | -1.5 |
| Cash from investing | 0.7 | -4.6 |
| Cash from financing | 5.1 | 1.5 |
| Capex | 1.1 | 5.0 |
| Free cash flow | 0.4 | -6.5 |
| Dividends paid | 0.0 | 0.0 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Onyx Biotec Limited | 63 | 34.60 | — | 1.13 | -0.4% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Onyx Biotec Limited?
Onyx Biotec Limited (ONYX) closed at ₹34.60 on NSE on 06 Nov 2026.
What is the market cap of Onyx Biotec Limited?
₹63 crore at the latest close.
How fast is Onyx Biotec Limited growing?
Onyx Biotec Limited: Latest-half-year revenue is up 9.7% year on year, profit down 65.0%.
How profitable is Onyx Biotec Limited?
On a trailing-twelve-month basis return on equity is -0.4%, return on capital employed 1.1%, operating margin 4.9%, net margin -0.3%.
How much debt does Onyx Biotec Limited have?
Onyx Biotec Limited is lightly geared: debt to equity is 0.27 with borrowings of ₹15 cr against cash of ₹4 cr (balance sheet of 2026-03-31). Operating profit covers interest 0.6 times.
Financials parsed from Onyx Biotec Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Half-yearly from H1 FY25, annual from FY25, balance sheet from Sep '24. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.